A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains spike proteins that assist the virus in entering host cells. In the absence of a specific intervention, efforts are afoot throughout the world to find an effective treatment for SARS-CoV-2. Through innovative techniques, monoclona...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Syed Mohammed Basheeruddin Asdaq, Syed Imam Rabbani, Meshary Alkahtani, Meshal Meshary Aldohyan, Abdullah Mohammad Alabdulsalam, Majed Sadun Alshammari, Saleh Ahmad Alajlan, Aljawharah Binrokan, Yahya Mohzari, Ahmed Alrashed, Mohammed Kanan Alshammari, Mohd. Imran, Naira Nayeem
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	monoclonal antibodies innovation patent reviews COVID-19 therapeutic application Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/0fb05dad1ca24fa887ff4317570027ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0fb05dad1ca24fa887ff4317570027ad
record_format	dspace
spelling	oai:doaj.org-article:0fb05dad1ca24fa887ff4317570027ad2021-11-11T17:22:19ZA Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-1910.3390/ijms2221119531422-00671661-6596https://doaj.org/article/0fb05dad1ca24fa887ff4317570027ad2021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11953https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains spike proteins that assist the virus in entering host cells. In the absence of a specific intervention, efforts are afoot throughout the world to find an effective treatment for SARS-CoV-2. Through innovative techniques, monoclonal antibodies (MAbs) are being designed and developed to block a particular pathway of SARS-CoV-2 infection. More than 100 patent applications describing the development of MAbs and their application against SARS-CoV-2 have been registered. Most of them target the receptor binding protein so that the interaction between virus and host cell can be prevented. A few monoclonal antibodies are also being patented for the diagnosis of SARS-CoV-2. Some of them, like Regeneron<sup>®</sup> have already received emergency use authorization. These protein molecules are currently preferred for high-risk patients such as those over 65 years old with compromised immunity and those with metabolic disorders such as obesity. Being highly specific in action, monoclonal antibodies offer one of the most appropriate interventions for both the prevention and treatment of SARS-CoV-2. Technological advancement has helped in producing highly efficacious MAbs. However, these agents are known to induce immunogenic and non-immunogenic reactions. More research and testing are required to establish the suitability of administering MAbs to all patients at risk of developing a severe illness. This patent study is focused on MAbs as a therapeutic option for treating COVID-19, as well as their invention, patenting information, and key characteristics.Syed Mohammed Basheeruddin AsdaqSyed Imam RabbaniMeshary AlkahtaniMeshal Meshary AldohyanAbdullah Mohammad AlabdulsalamMajed Sadun AlshammariSaleh Ahmad AlajlanAljawharah BinrokanYahya MohzariAhmed AlrashedMohammed Kanan AlshammariMohd. ImranNaira NayeemMDPI AGarticlemonoclonal antibodiesinnovationpatent reviewsCOVID-19therapeutic applicationBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11953, p 11953 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	monoclonal antibodies innovation patent reviews COVID-19 therapeutic application Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	monoclonal antibodies innovation patent reviews COVID-19 therapeutic application Biology (General) QH301-705.5 Chemistry QD1-999 Syed Mohammed Basheeruddin Asdaq Syed Imam Rabbani Meshary Alkahtani Meshal Meshary Aldohyan Abdullah Mohammad Alabdulsalam Majed Sadun Alshammari Saleh Ahmad Alajlan Aljawharah Binrokan Yahya Mohzari Ahmed Alrashed Mohammed Kanan Alshammari Mohd. Imran Naira Nayeem A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
description	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains spike proteins that assist the virus in entering host cells. In the absence of a specific intervention, efforts are afoot throughout the world to find an effective treatment for SARS-CoV-2. Through innovative techniques, monoclonal antibodies (MAbs) are being designed and developed to block a particular pathway of SARS-CoV-2 infection. More than 100 patent applications describing the development of MAbs and their application against SARS-CoV-2 have been registered. Most of them target the receptor binding protein so that the interaction between virus and host cell can be prevented. A few monoclonal antibodies are also being patented for the diagnosis of SARS-CoV-2. Some of them, like Regeneron<sup>®</sup> have already received emergency use authorization. These protein molecules are currently preferred for high-risk patients such as those over 65 years old with compromised immunity and those with metabolic disorders such as obesity. Being highly specific in action, monoclonal antibodies offer one of the most appropriate interventions for both the prevention and treatment of SARS-CoV-2. Technological advancement has helped in producing highly efficacious MAbs. However, these agents are known to induce immunogenic and non-immunogenic reactions. More research and testing are required to establish the suitability of administering MAbs to all patients at risk of developing a severe illness. This patent study is focused on MAbs as a therapeutic option for treating COVID-19, as well as their invention, patenting information, and key characteristics.
format	article
author	Syed Mohammed Basheeruddin Asdaq Syed Imam Rabbani Meshary Alkahtani Meshal Meshary Aldohyan Abdullah Mohammad Alabdulsalam Majed Sadun Alshammari Saleh Ahmad Alajlan Aljawharah Binrokan Yahya Mohzari Ahmed Alrashed Mohammed Kanan Alshammari Mohd. Imran Naira Nayeem
author_facet	Syed Mohammed Basheeruddin Asdaq Syed Imam Rabbani Meshary Alkahtani Meshal Meshary Aldohyan Abdullah Mohammad Alabdulsalam Majed Sadun Alshammari Saleh Ahmad Alajlan Aljawharah Binrokan Yahya Mohzari Ahmed Alrashed Mohammed Kanan Alshammari Mohd. Imran Naira Nayeem
author_sort	Syed Mohammed Basheeruddin Asdaq
title	A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
title_short	A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
title_full	A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
title_fullStr	A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
title_full_unstemmed	A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
title_sort	patent review on the therapeutic application of monoclonal antibodies in covid-19
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0fb05dad1ca24fa887ff4317570027ad
work_keys_str_mv	AT syedmohammedbasheeruddinasdaq apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT syedimamrabbani apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT mesharyalkahtani apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT meshalmesharyaldohyan apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT abdullahmohammadalabdulsalam apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT majedsadunalshammari apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT salehahmadalajlan apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT aljawharahbinrokan apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT yahyamohzari apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT ahmedalrashed apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT mohammedkananalshammari apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT mohdimran apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT nairanayeem apatentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT syedmohammedbasheeruddinasdaq patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT syedimamrabbani patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT mesharyalkahtani patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT meshalmesharyaldohyan patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT abdullahmohammadalabdulsalam patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT majedsadunalshammari patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT salehahmadalajlan patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT aljawharahbinrokan patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT yahyamohzari patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT ahmedalrashed patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT mohammedkananalshammari patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT mohdimran patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19 AT nairanayeem patentreviewonthetherapeuticapplicationofmonoclonalantibodiesincovid19
_version_	1718432102371819520

A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19

Ejemplares similares